{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:43:42Z","timestamp":1788403422542,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-022-02336-0","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T09:02:32Z","timestamp":1646125352000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata"],"prefix":"10.1007","volume":"315","author":[{"given":"Daniela","family":"Mikhaylov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Glickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle K.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba L.","family":"Posligua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra G.","family":"Florek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Ibler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika L.","family":"Hagstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Colavincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"issue":"4","key":"2336_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1067\/mjd.2000.103909","volume":"42","author":"S Madani","year":"2000","unstructured":"Madani S, Shapiro J (2000) Alopecia areata update. J Am Acad Dermatol 42(4):549\u2013566. https:\/\/doi.org\/10.1067\/mjd.2000.103909","journal-title":"J Am Acad Dermatol"},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","volume":"98","author":"T Simakou","year":"2019","unstructured":"Simakou T, Butcher JP, Reid S, Henriquez FL (2019) Alopecia areata: A multifactorial autoimmune condition. J Autoimmun 98:74\u201385. https:\/\/doi.org\/10.1016\/j.jaut.2018.12.001","journal-title":"J Autoimmun"},{"issue":"1","key":"2336_CR3","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP (2017) Alopecia areata. Nat Rev Dis Prim 3(1):17011. https:\/\/doi.org\/10.1038\/nrdp.2017.11","journal-title":"Nat Rev Dis Prim"},{"issue":"16","key":"2336_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","volume":"366","author":"A Gilhar","year":"2012","unstructured":"Gilhar A, Etzioni A, Paus R (2012) Alopecia areata. N Engl J Med 366(16):1515\u20131525. https:\/\/doi.org\/10.1056\/NEJMra1103442","journal-title":"N Engl J Med"},{"issue":"1","key":"2336_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L et al (2018) Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 78(1):1\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1141","journal-title":"J Am Acad Dermatol"},{"key":"2336_CR6","doi-asserted-by":"crossref","unstructured":"Zhao M, Wu R, Lu Q (2015) Chapter 14\u2014Epigenetics and other autoimmune skin diseases. In: Lu Q, Chang CC, Richardson BC (eds) Epigenetics and dermatology. Academic Press, pp 307\u2013326","DOI":"10.1016\/B978-0-12-800957-4.00014-X"},{"issue":"7","key":"2336_CR7","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","volume":"34","author":"Y Renert-Yuval","year":"2017","unstructured":"Renert-Yuval Y, Guttman-Yassky E (2017) The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther 34(7):1594\u20131609. https:\/\/doi.org\/10.1007\/s12325-017-0542-7","journal-title":"Adv Ther"},{"issue":"1","key":"2336_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1346-8138.2011.01476.x","volume":"39","author":"T Ito","year":"2012","unstructured":"Ito T (2012) Advances in the management of alopecia areata. J Dermatol 39(1):11\u201317","journal-title":"J Dermatol"},{"issue":"9","key":"2336_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","volume":"20","author":"C Goh","year":"2006","unstructured":"Goh C, Finkel M, Christos PJ, Sinha AA (2006) Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 20(9):1055\u20131060","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2336_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000296271","volume":"2","author":"SD Kuchabal","year":"2010","unstructured":"Kuchabal SD, Kuchabal D (2010) Alopecia areata associated with localized vitiligo. Case Rep Dermatol 2(1):27\u201331","journal-title":"Case Rep Dermatol"},{"issue":"6","key":"2336_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1365-4632.2005.01971.x","volume":"44","author":"A Kurtev","year":"2005","unstructured":"Kurtev A, Iliev E (2005) Thyroid autoimmunity in children and adolescents with alopecia areata. Int J Dermatol 44(6):457\u2013461. https:\/\/doi.org\/10.1111\/j.1365-4632.2005.01971.x","journal-title":"Int J Dermatol"},{"issue":"4","key":"2336_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jaip.2020.01.052","volume":"8","author":"K Kridin","year":"2020","unstructured":"Kridin K, Renert-Yuval Y, Guttman-Yassky E, Cohen AD (2020) Alopecia areata is associated with atopic diathesis: results from a population-based study of patients. J Allergy Clin Immunol Pract 8(4):1323\u20131328","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"15","key":"2336_CR13","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N et al (2016) Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI insight 1(15):e89790. https:\/\/doi.org\/10.1172\/jci.insight.89790","journal-title":"JCI insight"},{"issue":"2","key":"2336_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijwd.2017.07.001","volume":"4","author":"R Abedini","year":"2017","unstructured":"Abedini R, Hallaji Z, Lajevardi V, Nasimi M, Karimi Khaledi M, Tohidinik HR (2017) Quality of life in mild and severe alopecia areata patients. Int J Womens Dermatol 4(2):91\u201394. https:\/\/doi.org\/10.1016\/j.ijwd.2017.07.001","journal-title":"Int J Womens Dermatol"},{"issue":"5","key":"2336_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-4632.2004.02028.x","volume":"43","author":"AT G\u00fcle\u00e7","year":"2004","unstructured":"G\u00fcle\u00e7 AT, Tanr\u0131verdi N, D\u00fcr\u00fc \u00c7, Saray Y, Ak\u00e7al\u0131 C (2004) The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol 43(5):352\u2013356","journal-title":"Int J Dermatol"},{"issue":"4","key":"2336_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari A, Dai Z, Xing L et al (2015) Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib. EBioMedicine 2(4):351\u2013355. https:\/\/doi.org\/10.1016\/j.ebiom.2015.02.015","journal-title":"EBioMedicine"},{"issue":"1","key":"2336_CR17","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1038\/jidsymp.2013.14","volume":"16","author":"J Shapiro","year":"2013","unstructured":"Shapiro J (2013) Current treatment of alopecia areata. J Investig Dermatol Symp Proc 16(1):S42\u2013S44. https:\/\/doi.org\/10.1038\/jidsymp.2013.14","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"10","key":"2336_CR18","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamadermatol.2018.2312","volume":"154","author":"S Lee","year":"2018","unstructured":"Lee S, Kim BJ, Lee YB, Lee W-S (2018) Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol 154(10):1145\u20131151. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2312","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2336_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/ddg.12875","volume":"15","author":"K Jahn-Bassler","year":"2017","unstructured":"Jahn-Bassler K, Bauer WM, Karlhofer F, Vossen MG, Stingl G (2017) Sequential high- and low-dose systemic corticosteroid therapy for severe childhood alopecia areata. Journal der J German Soc Dermatol JDDG 15(1):42\u201347. https:\/\/doi.org\/10.1111\/ddg.12875","journal-title":"Journal der J German Soc Dermatol JDDG"},{"issue":"9","key":"2336_CR20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/1346-8138.13388","volume":"43","author":"T Yoshimasu","year":"2016","unstructured":"Yoshimasu T, Kanazawa N, Yamamoto Y, Furukawa F (2016) Multiple courses of pulse corticosteroid therapy for alopecia areata. J Dermatol 43(9):1075\u20131077","journal-title":"J Dermatol"},{"issue":"1","key":"2336_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/0974-7753.66911","volume":"2","author":"G Singh","year":"2010","unstructured":"Singh G, Lavanya M (2010) Topical immunotherapy in alopecia areata. Int J Trichol 2(1):36\u201339. https:\/\/doi.org\/10.4103\/0974-7753.66911","journal-title":"Int J Trichol"},{"issue":"3","key":"2336_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/15569527.2013.839997","volume":"33","author":"G Acikgoz","year":"2014","unstructured":"Acikgoz G, Caliskan E, Tunca M, Yeniay Y, Akar A (2014) The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol 33(3):247\u2013252. https:\/\/doi.org\/10.3109\/15569527.2013.839997","journal-title":"Cutan Ocul Toxicol"},{"key":"2336_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CCID.S22767","volume":"4","author":"A Alsantali","year":"2011","unstructured":"Alsantali A (2011) Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol 4:107\u2013115. https:\/\/doi.org\/10.2147\/CCID.S22767","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2336_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004413.pub2","author":"FM Delamere","year":"2008","unstructured":"Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J (2008) Interventions for alopecia areata. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004413.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2336_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","volume":"80","author":"K Phan","year":"2019","unstructured":"Phan K, Ramachandran V, Sebaratnam DF (2019) Methotrexate for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 80(1):120-127.e2. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.064","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2336_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L et al (2018) Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol 78(1):15\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1142","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2336_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","volume":"136","author":"M Suarez-Farinas","year":"2015","unstructured":"Suarez-Farinas M, Ungar B, Noda S et al (2015) Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing. J Allergy Clin Immunol 136(5):1277\u20131287. https:\/\/doi.org\/10.1016\/j.jaci.2015.06.032","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2336_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00403-015-1539-1","volume":"307","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhao Y, Ye Y et al (2015) Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata. Arch Dermatol Res 307(4):319\u2013331","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"2336_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jdermsci.2012.12.003","volume":"69","author":"T Ito","year":"2013","unstructured":"Ito T, Hashizume H, Shimauchi T et al (2013) CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci 69(2):140\u2013147. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.12.003","journal-title":"J Dermatol Sci"},{"issue":"4","key":"2336_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/exd.12918","volume":"25","author":"J Fuentes-Duculan","year":"2016","unstructured":"Fuentes-Duculan J, Gulati N, Bonifacio KM et al (2016) Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol 25(4):282\u2013286","journal-title":"Exp Dermatol"},{"key":"2336_CR31","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","volume":"10","author":"F Solimani","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K (2019) Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol 10:2847\u20132847. https:\/\/doi.org\/10.3389\/fimmu.2019.02847","journal-title":"Front Immunol"},{"issue":"9","key":"2336_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A et al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043\u20131049. https:\/\/doi.org\/10.1038\/nm.3645","journal-title":"Nat Med"},{"issue":"1","key":"2336_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000445182","volume":"8","author":"F Anzengruber","year":"2016","unstructured":"Anzengruber F, Maul JT, Kamarachev J, Tr\u00fceb RM, French LE, Navarini AA (2016) Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol 8(1):102\u2013106. https:\/\/doi.org\/10.1159\/000445182","journal-title":"Case Rep Dermatol"},{"issue":"12","key":"2336_CR34","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134(12):2988\u20132990. https:\/\/doi.org\/10.1038\/jid.2014.260","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2336_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","volume":"152","author":"A Dhayalan","year":"2016","unstructured":"Dhayalan A, King BA (2016) Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol 152(4):492\u2013493. https:\/\/doi.org\/10.1001\/jamadermatol.2015.3772","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2336_CR36","first-page":"47","volume":"26","author":"F Erduran","year":"2017","unstructured":"Erduran F, Ad\u0131\u015fen E, Aksakal AB (2017) Excellent response to tofacitinib treatment in a patient with alopecia universalis. Acta Dermatovenerol Alp Pannonica Adriat 26(2):47\u201349","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"3","key":"2336_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000450848","volume":"8","author":"SB Ferreira","year":"2016","unstructured":"Ferreira SB, Scheinberg M, Steiner D, Steiner T, Bedin GL, Ferreira RB (2016) Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report. Case Rep Dermatol 8(3):262\u2013266","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"2336_CR38","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/jdv.13598","volume":"30","author":"A Gupta","year":"2016","unstructured":"Gupta A, Carviel J, Abramovits W (2016) Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol 30(8):1373\u20131378","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"2336_CR39","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/exd.13060","volume":"25","author":"A Jabbari","year":"2016","unstructured":"Jabbari A, Nguyen N, Cerise JE et al (2016) Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol 25(8):642","journal-title":"Exp Dermatol"},{"issue":"2","key":"2336_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2340\/00015555-2491","volume":"97","author":"U Mrowietz","year":"2017","unstructured":"Mrowietz U, Gerdes S, Gl\u00e4ser R, Schr\u00f6der O (2017) Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol 97(2):283\u2013284","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"2336_CR41","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","volume":"77","author":"H-S Park","year":"2017","unstructured":"Park H-S, Kim M-W, Lee JS et al (2017) Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol 77(5):978\u2013980","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2336_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1203475418760512","volume":"22","author":"NU Patel","year":"2018","unstructured":"Patel NU, Oussedik E, Grammenos A, Pichardo-Geisinger R (2018) A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg 22(4):439\u2013442","journal-title":"J Cutan Med Surg"},{"issue":"15","key":"2336_CR43","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG et al (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI insight 1(15):e89776\u2013e89776. https:\/\/doi.org\/10.1172\/jci.insight.89776","journal-title":"JCI insight"},{"issue":"7","key":"2336_CR44","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J et al (2018) An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Investig Dermatol 138(7):1539\u20131545. https:\/\/doi.org\/10.1016\/j.jid.2018.01.032","journal-title":"J Investig Dermatol"},{"issue":"1","key":"2336_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.23871","volume":"90","author":"L Pieri","year":"2015","unstructured":"Pieri L, Guglielmelli P, Vannucchi AM (2015) Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol 90(1):82\u201383","journal-title":"Am J Hematol"},{"issue":"2","key":"2336_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40744-017-0069-z","volume":"4","author":"M Scheinberg","year":"2017","unstructured":"Scheinberg M, de Lucena Couto Oc\u00e9a RA, Cruz BA, Ferreira SB (2017) Brazilian experience of the treatment of alopecia universalis with the novel antirheumatic therapy tofacitinib: a case series. Rheumatol Ther 4(2):503\u2013508. https:\/\/doi.org\/10.1007\/s40744-017-0069-z","journal-title":"Rheumatol Ther"},{"issue":"8","key":"2336_CR47","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ced.13290","volume":"42","author":"M Vu","year":"2017","unstructured":"Vu M, Heyes C, Robertson S, Varigos G, Ross G (2017) Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol 42(8):942\u2013944","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2336_CR48","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","volume":"153","author":"O Ibrahim","year":"2017","unstructured":"Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF (2017) Treatment of alopecia areata with tofacitinib. JAMA Dermatol 153(6):600\u2013602","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2336_CR49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76(1):22\u201328. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2336_CR50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N et al (2016) Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74(2):370\u2013371","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2336_CR51","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","volume":"135","author":"E Higgins","year":"2015","unstructured":"Higgins E, Al Shehri T, McAleer MA et al (2015) Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Aller Clin Immunol 135(2):551-553.e3","journal-title":"J Aller Clin Immunol"},{"issue":"8","key":"2336_CR52","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/ijd.13598","volume":"56","author":"A Vandiver","year":"2017","unstructured":"Vandiver A, Girardi N, Alhariri J, Garza LA (2017) Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol 56(8):833\u2013835. https:\/\/doi.org\/10.1111\/ijd.13598","journal-title":"Int J Dermatol"},{"issue":"2","key":"2336_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000479722","volume":"4","author":"Y Ramot","year":"2018","unstructured":"Ramot Y, Zlotogorski A (2018) Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Skin Appendage Disord 4(2):122\u2013124. https:\/\/doi.org\/10.1159\/000479722","journal-title":"Skin Appendage Disord"},{"key":"2336_CR54","unstructured":"Baricitinib is first JAK-inhibitor to demonstrate hair regrowth in phase 3 alopecia areata (AA) trial (2021). https:\/\/investor.lilly.com\/news-releases\/news-release-details\/baricitinib-first-jak-inhibitor-demonstrate-hair-regrowth-phase. Accessed 3 Apr 2021"},{"key":"2336_CR55","unstructured":"A study of baricitinib (LY3009104) in adults with severe or very severe alopecia areata. https:\/\/ClinicalTrials.gov\/show\/NCT03899259"},{"issue":"10","key":"2336_CR56","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","volume":"5","author":"B Olamiju","year":"2019","unstructured":"Olamiju B, Friedmann A, King B (2019) Treatment of severe alopecia areata with baricitinib. JAAD Case Rep 5(10):892\u2013894. https:\/\/doi.org\/10.1016\/j.jdcr.2019.07.005","journal-title":"JAAD Case Rep"},{"key":"2336_CR57","unstructured":"Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in subjects with alopecia areata. https:\/\/ClinicalTrials.gov\/show\/NCT02974868"},{"key":"2336_CR58","unstructured":"Pfizer presents positive phase 2 data in alopecia areata during late-breaker session at the 27th European academy of dermatology and venereology (EADV) congress (2018). https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2018\/Pfizer-Presents-Positive-Phase-2-Data-in-Alopecia-Areata-During-Late-Breaker-Session-at-the-27th-European-Academy-of-Dermatology-and-Venereology-EADV-Congress\/default.aspx. Accessed 3 Apr 2021"},{"issue":"1","key":"2336_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","volume":"77","author":"CB Bayart","year":"2017","unstructured":"Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R (2017) Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 77(1):167\u2013170. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2336_CR60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","volume":"78","author":"LY Liu","year":"2018","unstructured":"Liu LY, Craiglow BG, King BA (2018) Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol 78(2):403-404.e1","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2336_CR61","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","volume":"78","author":"E Putterman","year":"2018","unstructured":"Putterman E, Castelo-Soccio L (2018) Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol 78(6):1207\u20131209e1","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2336_CR62","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","volume":"152","author":"BG Craiglow","year":"2016","unstructured":"Craiglow BG, Tavares D, King BA (2016) Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol 152(4):490\u2013491. https:\/\/doi.org\/10.1001\/jamadermatol.2015.4445","journal-title":"JAMA Dermatol"},{"key":"2336_CR63","unstructured":"ATI-502 topical solution for the treatment of alopecia areata (AA), alopecia universalis (AU) and alopecia totalis (AT). https:\/\/ClinicalTrials.gov\/show\/NCT03759340"},{"key":"2336_CR64","unstructured":"Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads (2019). https:\/\/endpts.com\/aclaris-hammered-as-hair-loss-drug-flops-in-phii-days-after-fda-took-issue-with-eskata-ads\/. Accessed 3 Apr 2021"},{"issue":"5","key":"2336_CR65","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam D (2019) JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 33(5):850\u2013856","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2336_CR66","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","volume":"144","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H, Nemoto O (2019) A Igarashi et al 2019 phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 144(6):1575\u20131583. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.004","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2336_CR67","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","volume":"82","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T (2020) Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol 82(4):823\u2013831. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2336_CR68","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjd.16014","volume":"178","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Nagata T (2018) Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol 178(2):424\u2013432. https:\/\/doi.org\/10.1111\/bjd.16014","journal-title":"Br J Dermatol"},{"issue":"5","key":"2336_CR69","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.18469","volume":"182","author":"M Worm","year":"2020","unstructured":"Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS (2020) Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol 182(5):1103\u20131110. https:\/\/doi.org\/10.1111\/bjd.18469","journal-title":"Br J Dermatol"},{"issue":"1","key":"2336_CR70","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2017.10.005","volume":"19","author":"K Malik","year":"2018","unstructured":"Malik K, Guttman-Yassky E (2018) Cytokine targeted therapeutics for alopecia areata: lessons from atopic dermatitis and other inflammatory skin diseases. J Investig Dermatol Symp Proc 19(1):S62\u2013S64. https:\/\/doi.org\/10.1016\/j.jisp.2017.10.005","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2336_CR71","unstructured":"LEO 124249 Ointment in the treatment of alopecia areata. https:\/\/ClinicalTrials.gov\/show\/NCT02561585"},{"issue":"6","key":"2336_CR72","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","volume":"133","author":"S Khattri","year":"2014","unstructured":"Khattri S, Shemer A, Rozenblit M et al (2014) Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 133(6):1626\u20131634. https:\/\/doi.org\/10.1016\/j.jaci.2014.03.003","journal-title":"J Allergy Clin Immunol"},{"issue":"Database issue","key":"2336_CR73","first-page":"D1049","volume":"43","author":"Gene OC","year":"2015","unstructured":"Gene OC (2015) Gene ontology consortium: going forward. Nucl Acids Res 43(Database issue):D1049\u2013D1056","journal-title":"Nucl Acids Res"},{"issue":"1","key":"2336_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"D Botstein","year":"2000","unstructured":"Botstein D, Cherry JM, Ashburner M et al (2000) Gene ontology: tool for the unification of biology. Nat Genet 25(1):25\u201329","journal-title":"Nat Genet"},{"issue":"D1","key":"2336_CR75","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M (2016) KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res 44(D1):D457\u2013D462","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2336_CR76","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45(D1):D353\u2013D361","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2336_CR77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1):27\u201330","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2336_CR78","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","volume":"10","author":"E Darwin","year":"2018","unstructured":"Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ (2018) Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichol 10(2):51\u201360. https:\/\/doi.org\/10.4103\/ijt.ijt_99_17","journal-title":"Int J Trichol"},{"issue":"6","key":"2336_CR79","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Delgocitinib: first approval. Drugs 80(6):609\u2013615. https:\/\/doi.org\/10.1007\/s40265-020-01291-2","journal-title":"Drugs"},{"issue":"2","key":"2336_CR80","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","volume":"84","author":"JW Glickman","year":"2020","unstructured":"Glickman JW, Dubin C, Renert-Yuval Y et al (2020) Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 84(2):370\u2013380","journal-title":"J Am Acad Dermatol"},{"key":"2336_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/all.14814","author":"JW Glickman","year":"2021","unstructured":"Glickman JW, Dubin C, Dahabreh D et al (2021) An integrated scalp and blood biomarker approach suggeststhe systemic nature of alopecia areata. Allergy. https:\/\/doi.org\/10.1111\/all.14814","journal-title":"Allergy"},{"issue":"9","key":"2336_CR82","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.3685","volume":"20","author":"SJ Divito","year":"2014","unstructured":"Divito SJ, Kupper TS (2014) Inhibiting Janus kinases to treat alopecia areata. Nat Med 20(9):989\u2013990","journal-title":"Nat Med"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-022-02336-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T22:27:37Z","timestamp":1676845657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-022-02336-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1007\/s00403-022-02336-0","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"26 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EGY is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Abbvie, Celgene, Eli Lilly, Janssen, Medimmune\/Astra Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, UCB. EGY is also a consultant for Sanofi Aventis, Regeneron, Stiefel\/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, Abbvie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. AP has received research funds (paid to institution) from AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, KrystalBio, Regeneron, UCB, is a consultant for Abbvie, Abeona, Alcimed, Almirall, Amagma, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingeheim, Castle Biosciences, Catawba, Dermira, Eli Lilly, Exicure, Forte, Kamari, Leo, Lifemax, NAOS, Novartis, Pfizer, Phoenix, Pierre Fabre, Regeneron, Sanofi\/Genzyme, Seanergy, Trifecta, UCB, and serves on a data safety monitoring board for AbbVie, Bausch, Galderma, Novan. The other authors declare that they have no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Reviewed and approved by local IRB. Written and verbal informed consent was given by all patients before inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}